Elisabet de los Pinos, President and CEO Aura Biosciences (NASDAQ: ), recently sold 15,955 shares of the company’s stock, valued at approximately $122,381. The biotechnology company, currently valued at $388 million, maintains a “FAIR” financial health rating according to InvestingPro analysis. The stock was sold at a weighted average price of $7.67, with transactions taking place between $7.67 and $7.72 per share. After the sale, de los Pinos directly holds 304,692 shares, with an additional 131,412 shares held indirectly through the Elisabet de los Pinos Revocable Trust. The sale was made to cover withholding tax obligations related to the acquisition of restricted stock units and was not discretionary. While the company faces profitability challenges, analysts maintain optimistic price targets in the range of $20 to $23 per share. InvestingPro subscribers can access additional insights on AURA’s financial health and growth prospects, including 6 key pro tips.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
